Skip to main content

Table 3 TESS score, BMI, QT interval and laboratory parameters at baseline, week 6 and week 12 in amisulpride and placebo groups

From: Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial

Item

Baseline

Week 6

Week 12

Group F(P)

Time F(P)

Group × time F(P)

Amisulpride

Placebo

Amisulpride

Placebo

Amisulpride

Placebo

TESS scorea

4.83 ± 3.81

4.93 ± 3.50

6.40 ± 4.82

5.40 ± 3.59

6.30 ± 4.76

5.55 ± 3.63

2.98 (0.42)

0.04 (0.96)

0.79 (0.38)

BMI

24.76 ± 3.47

23.06 ± 2.84

24.82 ± 3.39

23.10 ± 2.81

24.96 ± 3.45

23.19 ± 2.95

5.24 (0.03)

1.50 (0.23)

0.55 (0.58)

WBCa (× 109)

6.00 ± 1.21

6.53 ± 1.91

6.11 ± 1.45

6.59 ± 1.52

6.06 ± 1.49

7.06 ± 1.71

2.96 (0.09)

0.08 (0.92)

1.14 (0.33)

Neutrophilsa (× 109)

3.77 ± 0.81

4.15 ± 1.62

3.57 ± 1.22

4.12 ± 1.23

3.66 ± 1.00

4.56 ± 1.60

4.45 (0.04)

0.74 (0.48)

1.40 (0.25)

RBCa (× 1012)

4.11 ± 0.53

4.26 ± 0.51

4.14 ± 0.55

4.24 ± 0.50

4.20 ± 0.53

4.18 ± 0.46

0.68 (0.41)

0.04 (0.96)

1.81 (0.17)

Hba (g/L)

121.43 ± 13.60

128.85 ± 13.51

123.00 ± 14.33

129.62 ± 11.06

123.54 ± 14.16

129.62 ± 12.54

4.67 (0.03)

2.67 (0.08)

0.35 (0.70)

PLTa (× 109)

240.63 ± 57.46

261.26 ± 77.67

239.54 ± 63.58

261.59 ± 68.07

248.97 ± 69.62

252.59 ± 73.09

1.31 (0.26)

1.28 (0.28)

1.84 (0.17)

ALTa (U/L)

16.80 ± 10.57

19.97 ± 12.87

18.09 ± 13.33

19.97 ± 12.98

18.46 ± 11.64

21.88 ± 11.60

1.84 (0.18)

0.19 (0.83)

0.25 (0.78)

ASTa (U/L)

20.46 ± 6.35

23.38 ± 10.05

21.37 ± 9.81

19.85 ± 5.68

18.29 ± 4.96

21.85 ± 7.37

1.99 (0.16)

0.14 (0.87)

4.52 (0.02)

BUNa (mmol/L)

4.49 ± 1.20

4.03 ± 1.27

4.31 ± 0.90

4.35 ± 1.20

4.34 ± 1.39

4.18 ± 1.09

1.25 (0.27)

0.18 (0.84)

1.93 (0.15)

Cra (μmol/L)

62.74 ± 11.52

73.68 ± 15.22

63.34 ± 11.14

69.91 ± 19.03

62.17 ± 11.27

70.32 ± 16.36

6.31 (0.01)

0.29 (0.75)

2.01 (0.14)

Ura (μmol/L)

292.86 ± 91.53

352.26 ± 122.22

283.91 ± 90.78

359.24 ± 105.86

281.57 ± 98.38

333.00 ± 90.51

6.90 (0.01)

0.74 (0.48)

2.05 (0.14)

Glucosea (mmol/L)

5.11 ± 0.93

5.59 ± 2.02

5.29 ± 0.89

5.26 ± 0.83

5.34 ± 1.00

5.47 ± 1.02

0.45 (0.51)

1.09 (0.34)

0.93 (0.40)

TGa (mmol/L)

1.31 ± 0.53

1.59 ± 0.66

1.54 ± 0.74

1.74 ± 0.67

1.31 ± 0.68

1.62 ± 0.95

3.21 (0.08)

0.50 (0.61)

0.42 (0.66)

TCa (mmol/L)

4.03 ± 0.71

4.18 ± 0.94

4.03 ± 0.79

4.24 ± 0.86

4.03 ± 0.86

4.06 ± 0.65

0.11 (0.74)

3.14 (0.05)

1.93 (0.15)

HDLCa (mmol/L)

1.23 ± 0.43

1.18 ± 0.39

1.34 ± 0.48

1.18 ± 0.39

1.34 ± 0.48

1.12 ± 0.33

3.19 (0.08)

0.87 (0.43)

2.00 (0.14)

LDLCa (mmol/L)

2.11 ± 0.76

2.32 ± 0.95

2.23 ± 0.69

2.38 ± 0.74

2.17 ± 0.71

2.38 ± 0.70

0.81 (0.37)

0.31 (0.74)

0.10 (0.90)

QTc intervala (ms)

384.80 ± 30.67

411.79 ± 31.73

381.03 ± 29.58

413.24 ± 32.76

389.14 ± 31.77

408.41 ± 40.47

10.75 (0.002)

1.18 (0.31)

3.04 (0.06)

  1. Data were expressed as mean ± SD. aAdjusting for BMI [repeated-measures analysis of variance (RM ANOVA) with BMI as a covariate]. TESS Treatment Emergent Symptom Scale, BMI body mass index, WBC white blood cell, RBC red blood cell, Hb hemoglobin, PLT platelet, ALT alaninetransaminase, AST aspartate transaminase, BUN blood urea nitrogen, Cr creatinine, Ur uric acid, TG triglyceride, TC total cholesterol, HDLC high density lipoprotein, LDLC low density lipoprotein, QTc corrected QT